According to extravasation analysis, depletion of AF9 improved the luminal breast cancer cell dissemination capacity; in contrast, OE of AF9 impaired BLBC cell dissemination, suggesting that the AF9 expression level determines acquired metastatic capacity in vivo independent of the cell type (luminal breast cancer cells or BLBC cells). This evidence concerns the gene MLLT3 and breast carcinoma.